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A pragmatic randomised multi-centre trial
of multifamily and single family therapy for
adolescent anorexia nervosa
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Abstract
Background: Considerable progress has been made in recent years in developing effective treatments for child and
adolescent anorexia nervosa, with a general consensus in the field that eating disorders focussed family therapy (often
referred to as Maudsley Family Therapy or Family Based Treatment) currently offers the most promising outcomes.
Nevertheless, a significant number do not respond well and additional treatment developments are needed to
improve outcomes. Multifamily therapy is a promising treatment that has attracted considerable interest and we
report the results of the first randomised controlled trial of multifamily therapy for adolescent anorexia nervosa.
Methods: The study was a pragmatic multicentre randomised controlled superiority trial comparing two outpatient
eating disorder focussed family interventions - multifamily therapy (MFT-AN) and single family therapy (FT-AN). A total
of 169 adolescents with a DSM-IV diagnosis of anorexia nervosa or eating disorder not otherwise specified (restricting
type) were randomised to the two treatments using computer generated blocks of random sizes to ensure balanced
numbers in the trial arms. Independent assessors, blind to the allocation, completed evaluations at baseline, 3 months,
12 months (end of treatment) and 18 months.
Results: Both treatment groups showed clinically significant improvements with just under 60% achieving a good or
intermediate outcome (on the Morgan-Russell scales) at the end of treatment in the FT-AN group and more than 75%
in the MFT-AN group - a statistically significant benefit in favour of the multifamily intervention (OR = 2.55 95%; CI 1.17,
5.52; p = 0.019). At follow-up (18 months post baseline) there was relatively little change compared to end of treatment
although the difference in primary outcome between the treatments was no longer statistically significant. Clinically
significant gains in weight were accompanied by improvements in mood and eating disorder psychopathology.
Approximately half the patients in FT-AN and nearly 60% of those in MFT-AN had started menstruating.
Conclusions: This study confirms previous research findings demonstrating the effectiveness of eating disorder
focused family therapy and highlights the additional benefits of bringing together groups of families that maximises
the use of family resources and mutual support leading to improved outcomes.
Trial Registration: Current Controlled Trials ISRCTN11275465; Registered 29 January 2007 (retrospectively registered)
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Background
In the past 10–15 years there has been considerable pro-
gress in the evaluation of treatments for child and
adolescent anorexia nervosa (AN). In spite of this, the
gaps in our knowledge are still considerable. The only
treatment with significant support from randomised
controlled trials (RCTs) is family therapy (FT) [1–5].
Four studies have compared FT with individual therapy
or treatment as usual either as follow-up to inpatient
treatment [6, 7] or as stand-alone outpatient treatments
[8, 9] showing positive benefits for FT. Three studies
have compared different forms of family therapy [10, 11]
or different lengths of treatment of the same therapy
[12]. Four of the above studies [13–16] have completed
follow-ups of between 3–5 years showing low relapse rates
(of less than 10%) and continued improvements post
treatment. With one exception all the studies have used
an anorexia nervosa focused family therapy (FT-AN).1
Godart et al. [6] evaluated a FT that did not have an
eating disorders focus and still showed positive benefit
compared to treatment as usual. Agras et al. [11]
compared FT-AN with a generic systemic FT showing
generally similar outcomes between the two treatments
but with some advantages for FT-AN in faster weight
gain early on in treatment, fewer days in hospital if ad-
mission was needed and lower costs. While many of the
earlier studies had relatively small samples, the two most
recent studies [8, 11] had adequate power and confirm
the findings from earlier studies. Two individual treat-
ments have some support. The studies by Robin et al.
[9] and Lock et al. [8] used the same individual therapy
(called Ego Oriented Individual Therapy in the former
and Adolescent Focussed Therapy in the latter), which
while somewhat less efficacious than family therapy,
nevertheless, lead to a good outcome for a significant
number of patients. There is also some evidence in
support of CBT though there has only been one very small
RCT comparing CBT with FT showing no difference in
outcome [17] and an open follow up study [18], which
showed a positive treatment response in those who com-
pleted the full 40 week treatment (just under two thirds of
the sample) and ongoing improvements over the 60 week
follow-up. Apart from a somewhat lower retention rate in
treatment compared to most of the FT-AN studies
reported above, the CBT treatment was also more inten-
sive, requiring approximately twice the number of sessions
then is usually the case with FT-AN.
While the outcome results of FT-AN are encouraging,
not everyone responds, with 10–20% requiring add-
itional, more intensive treatment (medical stabilization
in hospital, inpatient psychiatric treatment or day care/
partial hospitalization) and 10–15% continue to need
ongoing treatment into adulthood [19]. In recent years
there has therefore been growing interest in modifying
or enhancing FT-AN that some families might need to
gain further benefit. These have included adding a focus
on addressing difficulties with emotional issues and
attachment patterns in the family [20, 21], further
strengthening parental management of feeding the
young person [22–24], and also bringing together groups
of families in a multi-family therapy context [25–27].
Multi family therapy for anorexia nervosa (MFT-AN)
draws on the same principles as FT-AN but is delivered
in a more intensive format to help families to overcome
a sense of isolation and stigmatization and to maximize
their own resources. Generally between 5–7 families take
part in MFT, sharing their experiences, learning by
example and learning from and providing support for one
another. In MFT-AN the principles of FT-AN [19, 28–30]
are integrated with more general concepts of MFT
[25–27, 31] as well a broad range of cognitive, psycho-
dynamic and group therapy conceptualizations and
intervention techniques. Several descriptive and open
follow-up studies have reported high levels of satisfaction
with the treatment and minimal dropouts [26, 32],
improvements in symptoms and interpersonal functioning
[32–35] and reductions in hospital readmission rates [36].
In this paper we describe the first RCT of MFT-AN
comparing its relative effectiveness with FT-AN. Our
primary hypothesis was that MFT-AN would be more
effective than FT-AN in restoring the young person
to a healthy nutritional state. A subsidiary hypothesis
was that those participating in MFT-AN would
express higher satisfaction with treatment compared
to those allocated to FT-AN.
Method
Participants and the context of the study
The study was a pragmatic multicentre randomised
controlled superiority trial comparing MFT-AN with
FT-AN. The trial was carried out in six specialist eating
disorders services in the National Health Service in the
UK providing treatment in a defined catchment area in
or near London. Patients invited to take part in the study
were consecutive referrals to the services, who met the
inclusion criteria. To be eligible for the study patients
had to be aged between 13-20 years,2 fulfil DSM-IV
criteria for anorexia nervosa or eating disorders not
otherwise specified (restricting type) and either be below
86% median BMI (%mBMI) for age and sex or had lost
15% body weight in the last three months. Patients were
excluded if they were in care, had a learning disability,
were suffering from psychosis, were alcohol or substance
dependent or had a coexisting medical condition that
might impact their weight (such as diabetes). We also
excluded patients who were seriously medically at risk
that is having a weight less than 67% mBMI or meeting
one or more criteria for medical instability eg dehydration
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(a postural drop of 20 mmHg), bradycardia (pulse rate
below 40 BPM), failed squat test (unable to get up without
using arms as levers), temperature below 34.5 °C
or electrolyte imbalance.
Therapists delivering the treatment were not selected
specifically for the study but included all the clinicians
routinely providing therapy in the participating services
(including trainees in the service). Training in both
treatments was provided by two of the study authors (IE,
EA) at the start of the study and regular six monthly
meetings of all trial therapists were used to ensure
consistency of approach across the centres was main-
tained. Within each service regular supervision was
provided for each treatment by experienced supervisors.
Both treatments are manualized [37].
To ensure that families did not have to wait unneces-
sarily long before being enrolled in a group the MFT
groups rotated between participating centres and were
comprised of families from across the centres. Groups
consisted of 5–7 families and could also include
non-trial families. Typically a group would contain 3–5
trial families. Two therapists always provided treat-
ment with the therapist pairings changing from group
to group.
Trial registration and ethical approval
The trial was registered with Current Controlled Trials
(registration number ISRCTN11275465) and with the
UK Clinical Research Network (UKCRN ID 6041).
Ethical approval for the study was given by the UK
Integrated Research Approval System Committee (04/
MREC/022). All participants gave written informed con-
sent having been provided details of the study and clear
information that deciding not to take part in the study
or withdrawing from the study at any point would have
no prejudicial effect on the treatment offered to them by
the participating services. For those under the age of 16,
consent was obtained from the young person’s parents
or legal guardians.
Treatments
Outpatient family therapy
Family therapy for adolescent anorexia nervosa (FT-AN)
[19, 29, 31] has been the focus of our previous treatment
trials [7, 10, 13, 38] – see also Eisler et al. [30] for an
account of the evolution of the treatment) and a treat-
ment manual has been developed to guide the therapists’
interventions [37]. Patients are seen with their families
over a period of 12 months. The number and frequency
of sessions is determined by clinical need starting ini-
tially with weekly meetings, which are then gradually
spread out to 3–4 weekly. These are mainly conjoint
family meetings although some individual sessions are
included where appropriate (particularly with older
adolescents at later stages of the treatment). The treat-
ment approach has the following key features:
a) A systems focus on understanding the family in the
context of a potentially life threatening illness where
the family is needed as a resource to help their child
recover, emphasizing that the family is not the cause
of the illness.
b) An emphasis on helping the parents to take a lead in
managing their child’s eating in the early stages of
treatment whilst stressing the temporary nature of
this role and making clear that this is an expression
of parental care rather than parental control.
c) Psychoeducation about the effects of starvation and
the role of predisposing personality traits for the
development of anorexia nervosa and comorbidities.
d) Use of externalisation of the illness using a range of
techniques including narrative externalising
conversations [39] that implies anorexia is a separate
entity, as well as discussions of the psychological
and physiological effects of starvation, which are
used purposefully to emphasize the role that
starvation has in influencing both behaviours and
cognitions, thereby shaping and reinforcing the
illness process.
e) In later stages of treatment a shifting of focus on
adolescent and family developmental life cycle
issues. The focus in this later stage is to help the
family to disentangle individual psychological
issues (eg self esteem, individuation, psychosocial
functioning) and family relationship issues from
the eating disorder behaviour and the interactional
patterns that have developed around it.
Multi-family therapy
Multi-family therapy for anorexia nervosa (MFT) [27, 31]
shares the main conceptual principles with FT-AN but
provides a more intensive form of treatment and allows
the family to draw on support from other families in the
group. The treatment starts with an intensive four day
multi-family programme for 5–7 families and is followed
by a further six one day meetings at 4–8 week intervals
over 9 months. Individual family meetings are scheduled
in the intervals between group meetings as needed with
the overall length of treatment for each family being
12 months. A wide range of intervention techniques is
used (including group, family, psycho-educational and cre-
ative techniques) combining multi-family sessions with
separate parent and adolescent sessions as well as activ-
ities targeted at individual families. There is also practical
input around managing mealtimes with multifamily meals
and ongoing discussions of what works best for each fam-
ily in how parents help their child overcome the fear of
eating and gaining weight.
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In addition to the general principles of FT-AN, de-
scribed above, MFT-AN includes the following [25, 27]:
a) Creating a sense of solidarity and reducing social
isolation and stigmatisation.
b) Stimulating new perspectives and providing a
context where families learn from each other.
c) Strengthening self-reflectiveness through observing
others, encouraging mutual support and feedback
and experimenting with cross-family exercises.
d) Discovering and building on competencies,
intensifying interactions and experiences and
practicing new behaviours in a safe space.
e) Raising expectations and hopes for recovery.
Families randomised to the MFT-AN group were all ini-
tially engaged in treatment individually until 5–7 families
had been recruited to create a new group (a new group
thereby starting approximately every six weeks). Families
were seen in between group meetings, the frequency and
overall number of such meetings determined by clinical
need although the expectation was that these sessions
would be less frequent than in the FT-AN group.
Assessments
Independent research assessors, who were blind to the
treatment allocations, conducted evaluations pre-
randomisation (baseline), at 3 months, 12 months (end of
treatment) and 18 months (6 month post treatment).
Every effort was made to include all patients in the follow-
up assessments, including those who discontinued
treatment early, to allow for an intention to treat analysis.
Primary outcome was defined using the Morgan/Russell
Global outcome scale [40] modified by Russell et al. [7] to
take account of bulimic symptoms which provides three
categories of outcome: Good outcome includes patients
whose weight is above 85% mBMI, who are menstruating
and have no bulimic symptoms. Those in the intermediate
outcome group meet the same weight criteria but are
either not menstruating or have occasional bulimic symp-
toms (averaging less than once a week over the past
month). Patients whose weight is below 85% mBMI or
have developed bulimic symptoms of once a week or more
are classified as having a poor outcome. The primary time
point of interest was the end of treatment (12 months post
randomisation).
Secondary outcomes of interest at 12 months and
18 months post randomisation were:
 Morgan/Russell Global outcome scale at 18 months.
 Weight data reported as a percentage of median
(ie 50th centile) BMI for young people of the same
height, age and sex, which takes into account that
BMI in children and adolescents changes with age.
The conversions to %mBMI were done using a
computer programme based on the Child Growth
Foundation [41] development charts.
 The Eating Disorder Examination [42], a well
validated interview measure of eating disorder
psychopathology, was administered at baseline,
12 months and 18 months. In addition to a global
scale there are 4 subscales (Restraint; Eating
Concern; Shape Concern and Weight Concern).
 Self-report measures completed by the young
people (administered at all four time points)
included:
o Beck Depression Inventory [43]
o Rosenberg Self-Esteem Scale [44]
 Parents completed the Experience of Caregiving
Inventory [45] (at baseline and 12 months) a
measure developed for the assessment of caregiving
demands with severely mentally ill patients adapted
for use in eating disorders [46].
 All participants also completed the Client Satisfaction
Questionnaire [47] at the end of treatment.
Randomisation
Random allocations of patients to trial arms at a 50:50
ratio were computer generated. Randomisation was
conducted in blocks of random sizes between 6 and 12
patients to ensure equal numbers of patients in the trial
arms. Once the initial assessment was carried out and
the patient was recruited to the trial, the trial
co-ordinator allocated the patient immediately to one of
the treatment groups using a randomisation database
created before the beginning of the study. This database
returned a patient's random group allocation once the
patient ID was entered and did not allow any changes to
the group allocation thereafter. The research workers
carrying out the assessments were blind to the alloca-
tion. The trial co-ordinator informed the therapist
assigned to the case who then contacted the family to
arrange the start of the allocated treatment.
Sample size calculation
For outpatients taking part in FT-AN we expected 63%
to reach a weight that is above 85% mBMI at the end of
treatment (12 months) based on Eisler et al. [10] and
Robin et al. [48]. Weight gain during MFT-AN had not
been studied in as much detail but our preliminary data
[26] suggested that 83% or more patients could be
expected to have reached a healthy weight within the
same period. We calculated that 77 participants would
be needed per trial arm for a two-sided chi-squared test
to detect such a difference with 80% power at a 5%
significance level. Allowing for 15% attrition to follow-
up required raising the number to 91 per trial arm (a total
sample size of n = 182).
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Statistical analysis
All formal statistical analyses were based on an intent-
to-treat principle with all participants analysed in the
treatment arm to which they were assigned. The primary
outcome was a binary variable contrasting good or inter-
mediate versus a poor outcome on the Morgan Russell
Global scale at the end of treatment, 12 months post-
randomisation, analysed using logistic regression. The
model contained trial arm, baseline status on the Morgan
Russell scale (binary variable), whether the patient had
previous treatment for eating disorder and time (months)
since diagnosis of the eating disorder as explanatory vari-
ables. The latter three baseline variables were included to
gain precision since they were known predictors of out-
come. We report inferences for the odds ratio of good/
intermediate outcome comparing MFT-AN with FT-AN
at 12 months. Odds presented are marginal population
odds derived from the (conditional) subject specific OR by
an approximate conversion formula [49]. We present mar-
ginal odds as representing the group difference in average
treatment effects on the population of ED patients (as op-
posed to the difference in individual change across time
described by conditional OR [49]).
Good or intermediate versus a poor outcome on the
Morgan Russell scale at 18 months post-randomisation
was also analysed using logistic regression. Other
continuous secondary outcomes were analysed using
analogous linear regression models. Normality of error
terms was checked using residual diagnostics.
To investigate drivers of loss-to-follow up in primary
and secondary outcomes, an indicator of missingness at
12 month was generated for each outcome variable.
Then logistic regressions were used to assess whether
there were any associations between baseline variables
or treatment adherence and missingness. Specifically,
the logistic regression model contained trial arm as a
predictor and added baseline variables and engagement
in treatment in a forward fashion to assess their predict-
ive power; with variables showing an association at the
liberal 15% level considered potential missingness
predictors. For this purpose engagement in treatment
was measured by a binary variable indicating whether or
not the family attended the full 12 months of treatment.
As incomplete engagement with treatment was found to
be predictive of missingness, we employed multiple
imputation (MI, with 100 imputations) which enabled us
to generate inferences that are valid under a missing at
random assumption (MAR) with the empirically identi-
fied variables (including post-randomisation treatment
engagement) being allowed to predict missingness [50].
Specifically the imputation step included all the variables
of the respective analyses model, further measures of the
outcome variable at other assessment time points and
the predictors of missingness.
Finally differences in carer and young person satisfac-
tion were investigated using regression of the CSQ dif-
ference scores between carer and young person. A
simple regression model testing whether the intercept
(of the difference scores) was different from 0 was used
in conjunction with MI. The statistical significance level
was set to 5%. All statistical analyses were carried out
in Stata 14.1 and R 3.2 (figures were produced with
ggplot2 [51]).
Results
Participant characteristics
Figure 1 shows the CONSORT diagram for the study -
359 adolescents were screened; 253 met the inclusion
criteria and 169 agreeing to take part in the study. Two
patients who agreed to participate and were randomised,
subsequently withdrew consent and did not contribute
to the analysis sample. A total of 167 adolescents took
part in the study (82 in FT-AN and 85 in MFT-AN).
Table 1 shows the participant demographic and clinical
characteristics. The mean age on entry to the study was
15.7 (SD 1.7), 91% were female, 70% came from intact
families and just under 10% had a non-white ethnic
background. The mean %mBMI on entry was 78.0 (SD
6.1) and the median duration of illness was 7 months.
Seventy six percent met diagnostic criteria for anorexia
nervosa the remaining were classified as EDNOS
(restricting type). Table 1 also shows that randomisation
produced reasonably balanced group with none of the
observed differences between the treatment groups
reaching statistical significance.
Engagement in treatment
Engagement with treatment was high with only 9
families in each group discontinuing treatment early (de-
fined as attending for < 3 months) ie less than 11% of
the total. We had hypothesised that the addition of the
MFT sessions would reduce the number of outpatient
sessions required but while the median number of
outpatient sessions attended in the MFT-AN group was
lower than in the FT-AN group (median18.5; IQR 11–24
compared to 19; IQR 12 - 27) the difference was not
statistically significant (Mann–Whitney test of group dif-
ference z = 0.99, p = 0.32). In addition to the single family
therapy sessions those in the MFT-AN group attended a
median 7 MFT days; IQR 1 – 10.
Loss to follow-up
There was little attrition with regard to the primary
Morgan Russell outcome and %mBMI (19 and 20 values
at end of treatment and 6 months post treatment respect-
ively) but loss to follow-up was considerable for secondary
outcome measures (median 88 values or 53% missing). A
number of baseline variables predicted missingness
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(family history of eating disorder, co-morbidity and birth
order in family). In particular not completing full
12 months of treatment was found to be a clear predictor
of missing outcome data on the Morgan Russell scale (OR
12.5, 95% CI: 1.49 to 104.9 z = −2.3, p = 0.02). We there-
fore employed multiple imputation to generate results that
are valid under less restrictive assumptions that allowed
for these variables to predict missingness (see Methods).
Categorised clinical outcome over the course of
treatment and six month follow-up
Figure 2 summarises the raw categorised outcome in the
two treatment groups at 3 months, 12 months (end of
treatment) and 18 months (six-month follow-up). Table 2
shows a statistically significant difference in the primary
outcome (rating on the Morgan-Russell Global outcome
scale at 12 months) in favour of MFT-AN with an odds
of a good or intermediate outcome in the MFT-AN
group 2.55 times higher than that of FT-AN (p = 0.018;
95% CI 1.17 to 5.52; p = 0.018). At 18 month follow-
up (secondary outcome) the odds ratio had dropped
to 2.01 and this weaker effect was not significant
(95% CI 0.91 to 4.45; p = 0.086). The distribution of
the outcome findings was similar across the different
treatment centres.
Changes in weight, eating disorder psychopathology,
depression and self-esteem
The adolescents in both treatment groups gained con-
siderable weight over the course of treatment and
follow-up (Fig. 3). Table 2 shows the results of the trial
arm comparisons at 12 months and 18 months and
Table 3 provides estimated changes in either trial arm
since baseline. At 12 months there were no statistically
significant differences between the two trial arms for
%mBMI, eating disorder psychopathology, depression
or self-esteem (Table 2). At 18 months there was a
significant difference in %mBMI favouring MFT-AN
(difference = 4.11; 95% CI 0.98, 7.24; p = 0.01). There were
no significant differences on any of the other measures.
Fig. 1 CONSORT Diagram
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The increase in weight resulted that in FT-AN 51.2%
had started menstruating at 12 months (not including
boys and those taking oral contraception) and 51.4%
18 months. In the MFT-AN group the figures were
56.3% at 12 months and 59% at 18 months.
A small number of the young people had developed
some bulimic symptoms – in FT-AN three at 12 months
and two at 18 months, in MFT-AN five (one of whom
would have met diagnostic criteria for bulimia nervosa)
at 12 months and three at 18 months.
There were significant improvements over time in
eating disorders psychopathology and depression in
both groups (Table 3). There were only small and non-
significant improvements in ratings of self-esteem over
time (Table 3) although it should be noted that the
average scores on this measure were in the normal
range already at baseline (Table 1).
Admissions to hospital during the study
A small number of patients needed to be admitted to
hospital during the course of treatment, three in the in
the MFT-AN group (2 ED related; 1 because of suicidal
risk) and two in the FT-AN group (both ED related).
Following discharge from hospital the patients contin-
ued with their outpatient treatment until the planned
end of treatment at 12 months. During the six month
follow-up period after the end of the planned out-
patient treatment there were six further admissions (2
in the MFT-AN arm and 4 in the FT-AN arm) – all six
patients had made poor progress in outpatient therapy
and had been categorised as having a poor outcome
at 12 months
Table 1 Baseline demographic and clinical factors
FT - AN
(N = 82)
MFT - AN
(N = 85)
Demographics
Age: mean (sd) 15.7 (1.6) 15.7 (1.7)
Female: n (%) 77 (93.9) 75 (88.2)
Ethnicity: n (%)
White 76 (92.7) 75 (88.2)
Other 3 (3.7) 3 (3.5)
Missing 3 (3.7) 7 (8.2)
Education: n (%)
Pre GCSE 54 (65.9) 60 (70.6)
Post GCSE 26 (31.7) 22 (25.9)
Missing 2 (2.4) 3 (3.5)
Parents: n (%)
Married / Cohabit 56 (68.3) 61 (71.8)
Separated / Divorced 24 (29.3) 24 (28.2)
One Parent Deceased 2 (2.4) 0 (0)
Clinical Characteristics
ED Age of onset (years): mean (SD) 14.3 (1.8) 14.5 (1.7)
Missing: n (%) 6 (7.3) 12 (14.1)
ED Duration (months): Median (IQR) 7 (4 – 11.5) 7 (3 – 11)
aMean (SD) 11.4 (12.6) 9.6 (10.5)
Missing: n (%) 6 (7.3) 12 (14.1)
Eating disorder: n (%)
Anorexia Nervosa 67 (81.7) 60 (70.6)
EDNOS (Restricting) 15 (18.3) 25 (29.4)
Prior Inpatient Treatment: n (%)
Yes 16 (19.5) 11 (12.9)
No 54 (66%) 57 (67%)
Missing 12 (14.6) 17 (20.0)
Co-morbid Depression: n (%)
Yes 10 (12.2) 2 (2.4)
No 57 (69.5) 66 (77.7)
Missing 15 (18.3) 17 (20.0)
Co-morbid OCD: n (%)
Yes 3 (3.7) 0 (0.0)
No 64 (78.1) 68 (80.0)
Missing 15 (18.3) 17 (20.0)
Co-morbid Anxiety: n (%)
Yes 1 (1.2) 0 (0.0)
No 66 (80.5) 68 (80.0)
Missing 15 (18.3) 17 (20.0)
Outcomes at baseline
%mBMI: mean (SD) 78.4 (5.8) 77.6 (6.3)
BMI: mean (SD) 15.8 (1.2) 15.7 (1.3)
Table 1 Baseline demographic and clinical factors (Continued)
EDE (restraint): mean (SD) 2.9 (1.7) 2.7 (1.8)
Missing: n (%) 10 (12.2) 10 (11.8)
EDE (eating concern): mean (SD) 2.1 (1.5) 1.9 (1.6)
Missing: n (%) 10 (12.2) 10 (11.8)
EDE (shape concern): mean (SD) 3.2 (1.9) 2.9 (1.8)
Missing: n (%) 10 (12.2) 10 (11.8)
EDE (weight concern): mean (SD) 2.8 (1.9) 2.5 (1.8)
Missing: n (%) 10 (12.2) 10 (11.8)
BDI: mean (SD) 25.2 (14.4) 23.9 (14.3)
Missing: n (%) 20 (24.4) 16 (18.8)
RSE: mean (SD) 26.3 (6.9) 25.1 (6.6)
Missing: n (%) 19 (23.2) 17 (20)
Abbreviations: %mBMI a percentage of median Body Mass Index for young
people of the same height, age and sex, EDE Eating Disorder Examination,
BDI Beck’s Depression Inventory, RSE Rosenberg Self Esteem Scale
abecause the duration of illness distribution is skewed, the median is the
appropriate measure of central tendency; most other studies have used the
mean (sd) value and we report this as well to provide comparison with
other reports
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Satisfaction with treatment
Data related to treatment satisfaction can be found in
Table 4. It is important to note that only 60% of parents
and 50% of the young people completed the treatment
satisfaction questionnaire and the findings therefore
need to be interpreted with considerable caution. Of
those who completed the measure more than 80% of
both young people and parents rated their satisfaction
with treatment as moderate to high (Table 4). However,
the prediction that those who took part in MFT-AN
would be more satisfied than those receiving FT-AN was
not confirmed either for young people or parents. The
Fig. 2 Distribution of Morgan Russell categorisation by trial arm
Table 2 Estimated mean outcome differences between treatment arms at end of treatment and follow-up
End of treatment (12 months post randomisation) Follow-up (18 months post randomisation)
Mean group difference
(95% CI)
Test Standardised
Coefficient
Mean group difference
(95% CI)
Test Standardised
Coefficient
Binary MR 2.55a (1.17, 5.52) t = 2.36 p = 0.018 - 2.01a (0.91, 4.49) t = 1.72 p = 0.086 -
%mBMI 2.24 (−0.47, 4.95) t = 1.62 p = 0.105 0.37b 4.11 (0.98, 7.24) t = 2.57 p = 0.010 0.68b
BMI 0.40 (−0.15, 0.94) t = 1.43 p = 0.15 0.37b 0.74 (0.12, 1.36) t = 2.35 p = 0.019 0.60b
EDE (restraint) 0.45 (−0.22, 1.11) t = 1.33 p = 0.185 0.26b 0.45 (−0.26, 1.15) t =1.25 p = 0.213 0.26b
EDE (eating concerns) 0.14 (−0.46, 0.73) t = 0.44 p = 0.659 0.087b 0.18 (−0.42, 0.78) t = 0.59 p = 0.559 0.12b
EDE (shape concerns) 0.54 (−0.18, 1.26) t =1.48 p = 0.139 0.30b 0.56 (−0.20, 1.31) t = 1.44 p = 0.150 0.30b
EDE (weight concerns) 0.44 (−0.27, 1.14) t = 1.22 p = 0.223 0.23b 0.49 (−0.31, 1.29) t =1.21 p = 0.226 0.26b
BDI 2.91 (−3.10, 8.91) t = 0.95 p = 0.342 0.20b 2.14 (−4.16, 8.44) t = 0.67 p = 0.504 0.15b
RSE −1.09 (−3.91, 1.73) t = −0.76 p0.447 −0.16b 0.5 (−2.45, 3.45) t = 0.33 p = 0.739 0.08b
ECI - Negative −2.22 (−17.1, 12.6) t = −0.30 p = 0.766 −0.07b - - -
ECI - Positive 0.71 (−2.07, 3.49) t = 0.51 p = 0.612 0.08b - - -
CSQ - Young Person −1.14 (−3.73, 1.45) t = −0.88 p = 0.382 −0.22c - - -
CSQ - Parent 0.64 (−1.51, 2.79) t = 0.5962 p = 0.556 0.13c - - -
Results are derived using multiple imputation with 100 imputations
Abbreviations: MR Morgan Russell Scale, %mBMI a percentage of median Body Mass Index for young people of the same height, age and sex, EDE Eating Disorder
Examination, BDI Beck Depression Inventory, RSE Rosenberg Self Esteem Scale, ECI Experience of Caregiving Inventory, CSQ Client Satisfaction Questionnaire
athe effect is expressed as a marginal odds ratio (OR); The conditional OR was 4.57 (95% CI 1.28, 16.44) at 12 m and 3.16 (95% CI 0.84, 11.82) 18 m
bstandardised coefficients were derived from dividing estimated difference by the standard deviation of the outcome variable at baseline
cstandardised coefficients were derived from dividing difference scores by the standard deviation of the control group (FT-AN)
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parents generally gave higher ratings with nearly 60% be-
ing highly satisfied, which was only true of just over 30%
of the young people. Comparing parental and young per-
son satisfaction, parental satisfaction was significantly
higher than young person’s satisfaction (mean = 2.3; 95%
CI 1.16, 3.46; p < 0.001). The difference between parental
and young person satisfaction was greater for MFT-AN
group (mean = 3.19; 95% CI 1.61, 4.76, p < 0.0001) than
for FT-AN (mean = 1.39; 95% CI −0.26, 3.04) although
this difference between groups did not reach statistical
significance (p = 0.118).
Discussion
This is the first randomised trial of multi-family therapy
for adolescent anorexia nervosa. The study confirms
findings from smaller open studies showing the utility of
the multi-family approach [32–35] and adds to the over-
all evidence for the effectiveness of family therapy in the
treatment of adolescent eating disorders [3–5]. The main
finding of the study is that while there were clinically
significant improvements in both treatments (just under
60% achieving a good or intermediate outcome at the
end of treatment in the FT-AN group and more than
75% in the MFT-AN group), there was a statistically sig-
nificant difference between the two treatment arms in
the primary outcome at end of treatment 12 months
post baseline. At follow-up (18 months post baseline)
there was relatively little change compared to end of
treatment although the difference in primary outcome
between the two treatments had dropped below the 0.05
level of statistical significance. Significant gains in weight
were accompanied by improvements in mood and eating
disorder psychopathology but of the secondary outcomes
only %mBMI at 18 months showed a statistically signifi-
cant greater improvement under MFT-AN compared to
FT-AN. Approximately half the patients in FT-AN and
nearly 60% of those in MFT-AN had started menstruat-
ing. Eight young people had some bulimic symptoms at
the end of treatment (one of whom would have met a
diagnosis of bulimia nervosa) and of these, five still had
such symptoms at 18 months. This is not unusual, as
the presentation of anorexia nervosa may change either
temporarily as part of the process of recovery or as a
transition from anorexia nervosa to a bulimia nervosa
diagnosis. The number developing BN symptoms in this
study (in both treatment arms) is relatively small but we
present these details to provide a more comprehensive
picture of the recovery process.
Two indicators showed the good acceptability of both
treatments – high treatment adherence rates (approxi-
mately 90% in each trial arm) and positive ratings on the
Client Satisfaction Inventory at the end of treatment. Our
prediction that families attending the multi-family treat-
ment would be more satisfied than those receiving singe
family therapy was not confirmed but a difference was
found between the ratings of parents and young people in
both treatments with parents most commonly rating
themselves as being highly satisfied whereas the young
people were more likely to return ratings of moderately
satisfied. While we are cautious about interpreting the
treatment satisfaction findings given the low number of
returned questionnaires, they are consistent with other
Fig. 3 Estimated weight gain over the course of treatment and follow-up. Symbols represent estimated means and error bars associated 95%
confidence intervals. Estimated means represent patients with the baseline mean %mBMI, mean time of eating disorder in months, no previous
treatment, no family history of eating disorder and eldest of birth order in family
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Table 3 Estimated mean changea from baseline at end of treatment (12 months) and follow-up (18 months)
End of treatment (12 months post randomisation) Follow-up (18 months post randomisation)
Group Observed:
n (%)
Mean Change
(95% CI)
Test Standardised
Coefficient
12m Predicted
Mean (95% CI)
Observed:
n (%)
Mean Change
(95% CI)
Test Standardised
Coefficientb
18 m predicted
mean (95% CI)
%mBMI
Baseline = 77.95
FT-AN 72 (88%) 10.84 (8.64, 13.04) t = 9.66 p < 0.001 1.79 88.78 (86.59, 90.98) 55 (67%) 9.63 (7.18, 12.08) t = 7.71 p < 0.001 1.59 87.58 (85.13, 90.03)
MFT-AN 75 (88%) 13.08 (10.98, 15.18) t = 12.22 p < 0.001 2.16 91.03 (88.94, 91.13) 60 (71%) 13.74 (11.41, 16.08) t = 11.53 p < 0.001 2.27 91.68 (89.33, 94.03)
BMI
Baseline = 15.7
FT-AN 72 (88%) 2.61 (2.16, 3.06) t = 11.31 p < 0.001 2.09 18.31 (17.86, 18.76) 55 (67%) 2.59 (2.10, 3.08) t =10.39 p < 0.001 2.07 18.29 (17.80, 18.78)
MFT-AN 75 (88%) 3.01 (2.59, 3.42) t =14.14 p < 0.001 2.41 18.71 (18.29, 19.12) 60 (71%) 3.33 (2.87, 3.79) t = 14.24 p < 0.001 2.66 19.03 (18.57, 19.49)
EDE (restraint)
Baseline = 2.78
FT-AN 38 (46%) −1.38 (−1.90, −0.86) t = −5.23 p < 0.001 −0.80 1.39 (0.88, 1.92) 32 (39%) −1.59 (−2.12 −1.04) t = −5.77 p < 0.001 −0.91 1.20 (0.66, 1.74)
MFT-AN 44 (52%) −0.93 (−1.42 −0.44) t = −3.76 p = 0.005 −0.52 1.85 (1.36, 2.34) 38 (45%) −1.14 (−1.64 −0.63) t = −4.45 p < 0.001 −0.75 1.64 (1.14, 2.15)
EDE (eating concerns)
Baseline = 2.01
FT-AN 38 (46%) −0.83 (−1.30 −0.35) t = −3.46 p < 0.001 −0.54 1.18 (0.71, 1.65) 32 (39%) −1.10 (−1.57 −0.64) t = −4.25 p < 0.001 −0.72 0.91 (0.44, 1.37)
MFT-AN 44 (52%) −0.70 (−1.13 −0.25) t = −3.10 p = 0.002 −0.45 1.32 (0.88, 1.76) 38 (45%) −0.92 (−1.35 −0.50) t = −4.25 p < 0.001 −0.605 1.09 (0.66, 1.51)
EDE (shape concerns)
Baseline = 1.83
FT-AN 37 (45%) −1.28 (−1.85 −0.71) t = −4.44 p < 0.001 −0.70 1.75 (1.18, 2.32) 32 (39%) −1.25 (−1.84 −0.66) t = −4.16 p < 0.001 −0.68 1.78 (1.19, 2.37)
MFT-AN 44 (52%) −0.74 (−1.28 −0.20) t = −2.70 p = 0.0072 −0.41 2.29 (1.75, 2.82) 38 (45%) −0.69 (−1.24 −0.15) t = −2.491 p < 0.013 −0.38 2.34 (1.79, 2.88)
EDE (weight concerns)
Baseline = 2.64
FT-AN 38 (46%) −1.03 (−1.57 −0.48) t = −3.67 p < 0.001 −0.54 1.62 (1.07, 2.16) 31 (38%) −0.88 (−1.50 −0.26) t = −2.80 p = 0.006 −0.47 1.76 (1.14, 2.38)
MFT-AN 44 (52%) −0.59 (−1.12 −0.06) t = −2.18 p = 0.029 −0.31 2.05 (1.52, 2.58) 37 (44%) −0.39 (−0.96, 0.18) t = −1.34 p = 0.181 −0.21 2.25 (1.68, 2.82)
BDI
Baseline = 24.47
FT-AN 35 (43%) −8.82 (−13.31 −4.33) t = −3.86 p < 0.001 −0.62 15.65 (11.2, 20.14) 37 (45%) −7.40 (−12.04 −2.75) t = - 3.13 p = 0.002 −0.52 17.07 (12.43, 21.72)
MFT-AN 41 (48%) −5.91 (−10.20 −1.63 t = −2.71 p = 0.007 −0.41 18.55 (14.27, 22.84) 33 (39%) −5.26 (−9.89 −0.62) t = −2.23 p = 0.026 −0.37 19.22 (14.6, 23.85)
RSE
Baseline = 25.68
FT-AN 36 (44%) −0.51 (-2.74, 1.72) t = −0.45 p = 0.653 –0.08 25.19 (22.96, 27.42) 37 (45%) –1.50 (–3.80, 0.79) t = –1.29 p = 0.199 –0.51 24.20 (21.90, 26.49)
MFT-AN 42 (49%) –1.60 (–3.65, 0.44) t =–1.54 p = 0.124 –0.24 24.10 (22.05, 26.14) 35 (41%) –1.00 (–3.11, 1.11) t = –0.93 p = 0.352 –0.15 24.70 (22.58, 26.18)
ECI (Negative)
Baseline = 85.56
FT-AN 44 (54%) –13.59 (–24.58,–2.59) t = −2.47 p = 0.016 −0.45 71.97 (60.98, 82.97)
MFT-AN 44 (52%) −15.81 (−26.88 −4.72) t = −2.86 p = 0.006 −0.52 69.75 (58.68, 80.83)
ECI (Positive)
Baseline = 28.27
FT-AN 47 (57%) 0.42 (−1.61, 2.45) t−0.41 p = 0.682 0.05 28.67 (26.66, 30.72)
MFT-AN 46 (54%) 1.13 (−0.99, 3.25) t−1.07 p = 0.291 0.13 29.40 (27.28, 31.52)
The number of observations is presented with percentage of observations possible in each treatment arm. Estimates are derived using multiple imputation with100 imputations
Abbreviations: %mBMI a percentage of median Body Mass Index for young people of the same height, age and sex, EDE Eating Disorder Examination, BDI Beck Depression Inventory, RSE Rosenberg Self Esteem Scale, ECI
Experience of Caregiving Inventory
aTo derive predicted mean change scores, continuous covariates were set at the mean of the sample at baseline and categorical values at the most frequent value: For each outcome, at the baseline mean of that
outcome and the following additional estimates: Eating disorder in months; mean 9.34, previous Eating Disorder patient: no, family history of Eating Disorder: birth order in family; eldest
bstandardised coefficients were calculated by dividing estimated mean change by the standard deviation of the outcome variable at baseline
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studies of family therapy for AN [52]. The good engage-
ment with outpatient treatment is also reflected in only
3% of patients requiring hospital admission during the
treatment phase of the study (and less then 7% for the
duration of the study as a whole).
Several limitations of the study need to be mentioned.
The recruited sample was close to the size required by
the power calculation for the purpose of the primary
analysis. However, the data collection of secondary out-
come variables turned out to be considerably lower than
we would have liked and the comparisons on these sec-
ondary outcomes therefore has reduced power and need
to be considered with caution. Our analyses also do not
take account of the fact that MFT-AN was delivered in
groups of families, as we had been unable to collect suf-
ficiently reliable information to allow us to account for
this in our analysis. However, as only a part of the ther-
apy was delivered in groups with typically 3–4 trial fam-
ilies participating in each group, and the therapist pairs
varied across groups we would not expect this to add
much variability to the data. The other significant limita-
tions is that the study funding allowed only for the com-
pletion of a six month follow-up period after treatment
completion and a longer follow would be required to de-
termine the longer term outcomes in the two
treatments.
The study also has a number of strengths. It is at
present one of the largest RCTs of adolescent AN
and because of the relatively few exclusions, with
only the most severely ill patients needing urgent
hospital admission (those below 67% mBMI or other
serious indications of medical instability) being ex-
cluded, can be considered largely representative of
the clinical population being studied. The pragmatic
design of the study meant that the treatments can
also be considered to represent the kind of treat-
ment that would be provided in specialist commu-
nity based ED services in the UK. For instance,
therapists were not recruited specifically for the
study and included all therapists in the participating
services including trainees. While the therapists re-
ceived additional training and ongoing supervision to
deliver the treatments in a manner consistent with
the treatment manuals, this is no different from
what would be expected in good services purporting
to provide evidence-based treatments.
Before drawing conclusions from the study, readers
will need to consider several issues. First, the design of
the study was such that the amount of treatment was
not fully determined by the study protocol but allowed
clinicians and the families to decide on the frequency of
sessions and this resulted in a somewhat higher amount
of therapy time in the MFT-AN arm of the trial and
some might argue that this in itself could explain the dif-
ferences in outcome between the study arms. In order
for this to be the case one needs to assume that there is
a direct and linear relationship between therapy contact
time and outcome, a problematic assumption that takes
no account of the fact that change does not happen sim-
ply in the context of therapy sessions or that increased
frequency of sessions may in some instances inhibit
change by fostering a dependence on therapy. In the
case of family therapy, which aims to mobilize the family
as a resource to promote change, it has long been ar-
gued that less frequent sessions particularly in later
stages of treatment are often more effective then very
frequent meetings as they encourage the family to draw
on their own resources which is consistent with the con-
ceptual framework of FT-AN [53]. There is also empir-
ical evidence from research by Lock and colleagues [12,
15] who compared in an RCT 10 and 20 sessions of FT-
AN and found no differences in overall outcome with
the higher number of sessions suggesting that increasing
the “dose” of therapy may not in itself be the key ingre-
dient of change. Nevertheless, the possibility cannot be
ruled out that at least some of the differences in
outcome between the two treatment arms in the current
study were due to increased therapeutic contact with
families.
Second, the proportions of those who responded well
to the treatment compared to those who had a poor out-
come has to be viewed in the context of our choice of
outcome criteria. Definitions of what constitutes a posi-
tive outcome in anorexia nervosa are as varied as the
terms that are used to describe this (good outcome, re-
covery, remission, partial remission). While nearly all
classification of outcome for anorexia nervosa use a
weight criterion as a key part of its definition this has
Table 4 Satisfaction with treatment
Client satisfaction questionnaire
FT-AN MFT-AN Total
Satisfaction score Young people Parents Young people Parents Young people Parents
8−20 (low) 5 (6.0%) 7 (8.4%) 8 (9.3%) 5 (5.8%) 14 (8.3%) 12 (7.1%)
21−26 (moderate) 19 (22.9%) 13 (15.7%) 21 (24.4%) 15 (17.4%) 39 (23.1%) 28 (16.5%)
27−32 (high) 13 (15.7%) 27 (32.5%) 13 (15.1%) 29 (33.7%) 26 (15.4%) 56 (33.1%)
Missing 46 (55.4%) 36 (43.4%) 44 (51.2%) 37 (43.0) 90 (53.3%) 73 (43.2%)
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varied widely from 85% expected weight to 95% or even
100%. To some extent the lack of agreement on what
constitutes a good outcome is simply a reflection of the
variability of weight in healthy individuals and the vari-
ability in the time lag once healthy weight is achieved
and the normalization of physical functions such as
menstruation and psychological aspects such as eating
disorder cognitions. While in the clinical context we can
tolerate the uncertainty of defining how well an individ-
ual patient may be doing at a particular point in time, in
a research setting we require clear definitions with the
consequence that some individuals will be misclassified.
The merit of the definition we have chosen is that it has
been shown to differentiate outcome between treatments
in a number of studies [6, 7] and more importantly that
it predicts long term outcome [14, 15]. While it does not
provide a direct comparison with studies using a higher
weight criterion to define remission, it is readily compar-
able to definitions of partial remission used in these
studies [8, 54].
Nevertheless, comparisons with the results of other
studies are not straightforward. Even when comparable
definitions of outcome are used, there is considerable
variability in the reported outcomes between studies [8,
11, 56]. There are likely to be a number of reasons for
this, including differences in demographics, methods of
study recruitment and perhaps most importantly differ-
ences in healthcare organization between different coun-
tries. Thus for instance the UK outpatient RCTs have
generally included samples with an average of 75–78%
mBMI at baseline [10, 38, 55], whereas in the US and
Australian studies baseline weights tend to be higher,
ranging on average between 82–86% mBMI [8, 11, 12,
48, 56]. This difference is primarily determined by the
way hospital admissions are used in the treatment of an-
orexia nervosa in different countries. In the US, patients
below 75% are generally excluded from outpatient studies
(though may be included following a brief admission to
increase their weight above this threshold) whereas the
UK outpatient studies have generally included patients at
lower weights (and only admitted to hospital if other cri-
teria of medical instability are present). Similarly, in the
US and Australian studies the number of hospital admis-
sions during trials tend to be higher than in the UK al-
though these admissions are generally very brief. In the
UK studies while admissions are mostly less frequent they
tend to be longer. We do not know what effect these dif-
ferences are likely to have on the process of recovery and
the weight that patients reach at the end of treatment
which not only makes comparisons with other studies dif-
ficult but also limits the generalizability of the study find-
ings from one health service context to another [57].
Treatment outcome is also likely to be influenced by
other factors such duration of illness [58]. The duration of
illness in the present study is comparable to most of the
published adolescent AN RCTs and is also consistent with
service level research in the UK [57, 59]. However, a re-
cent study in Germany found that the duration of illness
before first treatment of young people with AN in a num-
ber of different treatment settings was nearly 2–3 times as
long [60], again highlighting the need for caution in gener-
alizing findings across different healthcare settings.
Conclusions
The outcome results of the current study in both treat-
ments but particularly the MFT-AN arm compare well
with other adolescent RCTs, especially considering the
low baseline weights of the study participants. However,
given the above caveats in mind and the fact that this is
still the only RCT of MFT-AN we are cautious in our
conclusions. Moreover, the study inevitably raises many
new questions. In this study the MFT-AN trial arm com-
bined single and multi family sessions reflecting the way
in which MFT-AN has been developed at the Maudsley
Hospital. Other services have in the mean time applied
the MFT model in different ways using MFT-AN as a
standalone outpatient treatment [32, 34, 36] or as part of
day care [33] or inpatient treatment [61]. Our study in-
cluded only young people with a diagnosis of AN or
restricting EDNOS (again reflecting the current clinical
practice at the Maudsley service) while others have uti-
lised the multifamily interventions with mixed ED diag-
noses groups. In a recent paper [62], we have described
MFT aimed specifically at adolescents suffering from
BN, which is less intensive than MFT-AN and includes
CBT and DBT components in the treatment. The
current study shows that the particular combination of
intensive MFT-AN with ongoing single FT-AN and
MFT-AN meetings improves outcomes at end of treat-
ment compared to FT-AN and highlights the benefits of
bringing groups of families together as a potentially
powerful treatment resource. A great deal more research
is needed, however, to identify how this resource can
best be utilised in different clinical contexts and with
different ED clinical groups.
Endnotes
1Various labels have been used for eating disorder fo-
cussed family therapy including Maudsley Family Ther-
apy, Maudsley Model Therapy and in recent years most
commonly Family Based Treatment or FBT. We have ar-
gued [19] that such terms are misleading because they
imply a theoretically distinct model of treatment rather
than a treatment with a shared theoretical frame with
other systemic therapies but with a specific focus on
treating an eating disorder (very much in the way that
“anxiety focussed CBT” or “trauma focussed CBT” are
both forms of CBT). The term FBT is also ambiguous
Eisler et al. BMC Psychiatry  (2016) 16:422 Page 12 of 14
because it is sometimes used just to refer to treatments
using a specific treatment manual [63] and sometimes to
all studies using an eating disorders focussed family
therapy. Our use of the term FT-AN emphasizes that
this is a treatment that draws on family systems theory
and uses a broad range of family therapy intervention
techniques while its specificity derives from its focus on
treating an eating disorder [64].
2While most adolescent studies have used 18 years as
their upper age limit we decided to include a broader
age range for two main reasons. First, 18 years is an ar-
bitrary boundary that reflects some changes in a young
person’s legal status but certainly does not reflect ei-
ther a social or biological maturational boundary
between adolescence and adulthood. Second, there is
increasing recognition that transitions between adoles-
cent and adult services need to be more flexible and
we therefore wanted to make sure that our findings
would be applicable beyond the narrowly defined
boundary between services.
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